Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

First Large Study Comparing Leading Hepatitis C Therapies Provides

Important Insights to Help Guide Clinical Practice

MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Final results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C, were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), providing important insights that may help guide clinical practice for physicians worldwide treating this serious and potentially life-threatening disease.

The IDEAL study compared combination therapy with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP),(1) as well as a lower dose of PEGINTRON in an investigational combination with REBETOL. The results showed that sustained virologic response (SVR),(2) the primary endpoint of the study, was similar for all three treatment regimens. The study also showed in secondary analyses that PEGINTRON combination therapy provided greater predictability of response at important treatment milestones and significantly lower relapse rates after the end of treatment than Pegasys and Copegus combination therapy, despite patients in the Pegasys arm overall receiving a significantly higher median ribavirin dose over the duration of the study. Safety and tolerability were similar among the treatment arms.

"IDEAL provides important insights about the similarities and differences of the two leading combination therapies for hepatitis C, and how physicians can use these findings to help manage their patients," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute.

In IDEAL (Individualized Dosing Efficacy vs. flat dosing to assess optimaL pegylated interferon therapy), 3,070 previously untreated U.S. patients with HCV genotype 1, the most co
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans believe ... is a serious public health and safety issue in ... a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse ... with this very serious health situation facing our country," ...
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 Key West ... care experts revealed their much anticipated study results of ... skin today and released an accompanying infographic on their ... in can have a major impact on the skin ... wrinkles and more. , When asked how they determined ...
(Date:8/22/2014)... (ESMO), the leading pan-European organisation representing medical oncology ... individuals receiving the Society,s esteemed annual awards. The ... Joensuu and Peter Boyle on the occasion of ... , Carsten Bokemeyer will receive the ESMO Award ... cancer discovery into real benefit at patient level. ...
(Date:8/22/2014)... provides insight on how the brain processes external input ... and sides of the body, in order to select ... in the journal Neuron , show that the ... of sensory information, with specialised functional roles for the ... input structure in the basal ganglia, and is typically ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... News) -- The air in American cities is getting ... Thursday. Significant progress has been made in reducing ... decades, the agency said in a news release. ... reduction in mercury from human sources such as coal-fired ... 84 percent fall in lead, which harms brain development ...
Breaking Medicine News(10 mins):Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:The striatum acts as hub for multisensory integration 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Sept. 14 The following is a,Statement by Oscar S. Wyatt, Jr.: "I,ve seen some ... politicians who want to,return those funds received from me, please return them in the form of ... ... Medical Foundation ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) management will be ... 43rd Annual Meeting of the European,Association for the Study ... a.m. PT / 1:30 p.m. CET local time in ... and recordings will be made,available following the event. The ...
... defects, U.S. experts say , , FRIDAY, Sept. 14 (HealthDay News) ... women since the federal government mandated folate fortification to prevent ... is enough -- or too much. , A new study ... finds that the number of women of childbearing age who ...
... Most people looking for tax advice,usually go to ... right? Here,s more on a new report that shows ... are actually not seeing the pros,trained in their field. ... Registered journalists can access video, audio, text, ...
... Blue Cross and Blue,Shield Association (BCBSA) convened a ... D.C., to discuss how insurers, doctors and hospitals,are ... safety.,Representatives from the Premier Inc. healthcare alliance, Duke ... Alabama, and WellPoint, Inc.,participated in the event. ...
... between the two protective treatments , FRIDAY, Sept. 14 (HealthDay ... a pill called dabigatran etexilate (DE) is just as effective ... blood clots after total hip replacement surgery. , As reported ... study included almost 3,500 hip replacement patients who received either ...
Cached Medicine News:Health News:Women's Folic Acid Levels Improving 2Health News:Women's Folic Acid Levels Improving 3Health News:Women's Folic Acid Levels Improving 4Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 2Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 3Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 4Health News:Pill Equals Injection in Preventing Clots After Hip Replacement 2
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: